Summit Therapeutics posts HARMONi-6 ASCO 2026 plenary slides on ivonescimab in squamous NSCLC

Summit Therapeutics

Summit Therapeutics

SMMT

0.00
  • Summit Therapeutics published Phase 3 HARMONi-6 overall survival results for ivonescimab with chemotherapy in first-line advanced squamous NSCLC.
  • Ivonescimab, a PD-1/VEGF bispecific antibody, showed a significant overall survival benefit versus tislelizumab with chemotherapy.
  • Earlier interim data showed median PFS of 11.1 months versus 6.9 months; HR 0.60; p<0.0001.
  • The double-blind trial enrolled 532 patients, testing ivonescimab 20 mg/kg every three weeks versus tislelizumab 200 mg every three weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief on May 31, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.